Literature DB >> 12422609

Sensitivity of culture and polymerase chain reaction for the etiologic diagnosis of erythema migrans.

Anamarija Zore1, Eva Ruzić-Sabljić, Vera Maraspin, Joze Cimperman, Stanka Lotric-Furlan, Andreja Pikelj, Tomaz Jurca, Mateja Logar, Franc Strle.   

Abstract

Skin biopsy samples from 150 patients with typical cutaneous manifestation of Lyme borreliosis, erythema migrans, were cultivated for the presence of Borrelia burgdorferi sensu lato in modified Kelly Pettenkofer (MKP) medium and analysed with two different polymerase chain reactions using either flagellin or nested OspA primers. Cultivation was successful in 75 of 150 (50%) skin samples. Out of 70 strains that were typed using PFGE, B. afzelii was identified in 60 (86%), B. garinii in 10 (14%) specimens, while no B. burgdorferi sensu stricto strains were found. B. burgdorferi sensu lato DNA was detected with polymerase chain reaction in 28% and 61% of skin samples, using flagellin and nested OspA primers, respectively. Concordant results in all three procedures employed in the present study were found in 62 (41%) specimens: 25/150 (17%) were positive with all three methods and 37/150 (25%) samples were completely negative.

Entities:  

Mesh:

Year:  2002        PMID: 12422609

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  11 in total

1.  [Cutaneous manifestations of Lyme disease : Pitfalls in the serological diagnostic workup].

Authors:  M Glatz; R R Müllegger
Journal:  Hautarzt       Date:  2017-04       Impact factor: 0.751

2.  In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy.

Authors:  Klaus-Peter Hunfeld; Eva Ruzic-Sabljic; Douglas E Norris; Peter Kraiczy; Franc Strle
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

Review 3.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

Review 4.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

5.  Improvement in the laboratory recognition of lyme borreliosis with the combination of culture and PCR methods.

Authors:  Tomasz Chmielewski; Janusz Fiett; Marek Gniadkowski; Stanislawa Tylewska-Wierzbanowska
Journal:  Mol Diagn       Date:  2003

6.  Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis.

Authors:  Tjasa Cerar; Katarina Ogrinc; Joze Cimperman; Stanka Lotric-Furlan; Franc Strle; Eva Ruzić-Sabljić
Journal:  J Clin Microbiol       Date:  2008-08-20       Impact factor: 5.948

Review 7.  Laboratory Diagnosis of Lyme Borreliosis.

Authors:  John A Branda; Allen C Steere
Journal:  Clin Microbiol Rev       Date:  2021-01-27       Impact factor: 26.132

Review 8.  Lyme disease: a review.

Authors:  Adriana R Marques
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.919

9.  Clinical characteristics associated with Borrelia burgdorferi sensu lato skin culture results in patients with erythema migrans.

Authors:  Franc Strle; Lara Lusa; Eva Ružić-Sabljić; Vera Maraspin; Stanka Lotrič Furlan; Jože Cimperman; Katarina Ogrinc; Tereza Rojko; Jerneja Videčnik Zorman; Daša Stupica
Journal:  PLoS One       Date:  2013-12-26       Impact factor: 3.240

10.  Comparison of detection of Borrelia burgdorferi DNA and anti-Borrelia burgdorferi antibodies in patients with erythema migrans in north-eastern Poland.

Authors:  Anna Moniuszko; Justyna Dunaj; Joanna Zajkowska; Piotr Czupryna; Renata Świerzbińska; Katarzyna Guziejko; Piotr Aleksiejczuk; Gerald Barry; Maciej Kondrusik; Sławomir Pancewicz
Journal:  Postepy Dermatol Alergol       Date:  2015-02-01       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.